For Protection Against Neuroinfections
Researchers from I.Y. Postovsky Organic Synthesis Institute, Urals Department of RAS and Urals Federal University, studying an antiviral agent of azoloazin group Triazavirin for treatment of different forms of influenza (including swine and avian flu) have obtained two candidate molecules: Mactavir and Mactavirine.
These substances are effective against tick-, mosquito- and rodent-borne infections. They are suggested to be able to protect the host from diseases affecting the central nervous system – Dengue fever, West Nile fever, Zika fever, tick-borne encephalitis.
Alexander Petrov, Chairman of Medsintez comments: “As we developed Triazavirine, at the first step we developed about 100 compounds. We studied their effects on viruses at the Virology center of the Ministry of Defense of the RF. Finally, we selected 15 compounds with highest antiviral activity. Out of those we selected two molecules showing a 96-99% activity against West Nile fever.”
Currently the rights for invention below to a Skolkovo resident (Azol Pharma), that develops a technology of obtaining finished drug forms.
The formulation of a new drug against neuroinfections is expected to be obtained before the end of the year. The next step will be to perform preclinical trials, then test batches for clinical trials, which will take five more years.
Patents for new substances have already been received in Russia. Applications for the discovery (European, Eurasian, American) have been submitted.